Form 13-F position report

CONTEXT THERAPEUTICS INC

Reported by Affinity Asset Advisors LLC

CNTX CUSIP 21077P108 Manager CIK 0001773195

Reported 660,589 shares, down 354,751 (34.9%) from the prior quarter.

Reported value -62.1%; share count -34.9% vs. the prior quarter.

Reduced
% of reported 13F value 0.04% This manager · Q1 2025
Shares 660,589 Quarter-end amount reported
Reported value $404,280 Fair value at quarter end
Consecutive quarters held 13 Through Q1 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-03-31 1687000
2022-06-30 1873000
2022-09-30 981000
2022-12-31 583653
2023-03-31 0
2023-06-30 428118
2023-09-30 496514
2023-12-31 371563
2024-03-31 453767
2024-06-30 3246376
2024-09-30 2589460
2024-12-31 1066107
2025-03-31 404280
2025-06-30 339410
2025-09-30 390090
2025-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarterly reported position history for CONTEXT THERAPEUTICS INC held by Affinity Asset Advisors LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2025 Reduced 0 -402,653 (-100.0%) 0 $0 2026-02-13
Q3 2025 Reduced 402,653 -115,372 (-22.3%) 0.03% $390,090 2025-11-13
Q2 2025 Reduced 518,025 -142,564 (-21.6%) 0.05% $339,410 2025-08-13
Q1 2025 Reduced 660,589 -354,751 (-34.9%) 0.04% $404,280 2025-05-14
Q4 2024 Reduced 1,015,340 -305,813 (-23.1%) 0.14% $1,066,107 2025-02-13
Q3 2024 Reduced 1,321,153 -297,987 (-18.4%) 0.35% $2,589,460 2024-11-13
Q2 2024 Added 1,619,140 +1,290,323 (392.4%) 0.37% $3,246,376 2024-08-14
Q1 2024 Unchanged 328,817 0 (0.0%) 0.06% $453,767 2024-05-14
Q4 2023 Unchanged 328,817 0 (0.0%) 0.07% $371,563 2024-02-13
Q3 2023 Added 328,817 +61,243 (22.9%) 0.14% $496,514 2023-11-14
Q2 2023 New 267,574 +267,574 (0.0%) 0.15% $428,118 2023-08-14
Q1 2023 Reduced 0 -883,654 (-100.0%) 0 $0 2023-05-15
Q4 2022 Unchanged 883,654 0 (0.0%) 0.23% $583,653 2023-02-13
Q3 2022 Unchanged 883,654 0 (0.0%) 0.27% $981,000 2022-11-14
Q2 2022 Added 883,654 +106,044 (13.6%) 0.79% $1,873,000 2022-08-12
Q1 2022 New 777,610 +777,610 (0.0%) 0.27% $1,687,000 2022-05-13

Who else reported the position

55 managers reported CONTEXT THERAPEUTICS INC for Q1 2025.

Managers reporting CONTEXT THERAPEUTICS INC in Q1 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BIOIMPACT CAPITAL LLC Unchanged 14,705,882 0 1.55% $9,000,000 2 qtrs
Avidity Partners Management LP Unchanged 7,477,200 0 0.87% $4,576,046 4 qtrs
Nextech Invest Ltd New 7,419,355 +7,419,355 1.06% $4,540,645 1 qtr
Deep Track Capital LP Unchanged 7,419,355 0 0.15% $4,540,645 4 qtrs
Blue Owl Capital Holdings LP Added 7,367,906 +1,009,978 1.45% $4,509,158 4 qtrs
GREAT POINT PARTNERS LLC Unchanged 4,683,711 0 1.52% $2,866,431 4 qtrs
FRANKLIN RESOURCES INC Unchanged 4,003,380 0 < 0.01% $2,450,069 3 qtrs
VANGUARD GROUP INC Reduced 3,253,467 -1,996 < 0.01% $1,991,122 14 qtrs
Blackstone Inc Unchanged 2,440,330 0 < 0.01% $1,493,482 4 qtrs
Nantahala Capital Management LLC Unchanged 1,935,484 0 0.05% $1,196,807 4 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2025
Filed
May 14, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
660,589
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.